North America SGLT2 Inhibitors Market

1. North America SGLT2 Inhibitors Market North America SGLT2 Inhibitors Market Size Worth USD 16.37 Billion by 2034 | CAGR: 8.4% North America SGLT2 Inhibitors Market Share, Size, Trends, Industry Analysis Report: By Indication [Cardiovascular, Chronic Kidney Disease (CKD), Type 2 Diabetes, and Others], Drug, Distribution Channel, and Country (US and Canada) – Market Forecast, 2025–2034

3. North America SGLT2 Inhibitors Market • The North America SGLT2 inhibitors market size was valued at USD 7.32 billion in 2024. The market is projected to grow from USD 7.93 billion in 2025 to USD 16.37 billion by 2034, exhibiting a CAGR of 8.4% during 2025–2034. Request To Sample : https://www.polarismarketresearch.com/industry-analysis/north- america-sglt2-inhibitors-market/request-for-sample

4. North America SGLT2 Inhibitors Market Key Market Players : • AstraZeneca • Boehringer Ingelheim International GmbH • Bristol-Myers Squibb Company • Eli Lilly and Company • Glenmark Pharmaceuticals Ltd. • Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.) • Lexicon Pharmaceuticals, Inc. • Merck & Co., Inc. • Sanofi • Pfizer Inc.

5. North America SGLT2 Inhibitors Market North America SGLT2 Inhibitors Market Report Highlights: • By drug, in 2024, the Jardiance (Empagliflozin) segment accounted for the largest revenue share of the North America SGLT2 inhibitors market. Jardiance's robust clinical profile demonstrates significant benefits in reducing cardiovascular mortality and heart failure hospitalizations, making it a preferred choice for managing type 2 diabetes and associated cardiovascular risks. • The type 2 diabetes segment, based on indication, is expected to register the highest CAGR during the forecast period. Governments and healthcare organizations in North America implement policies and programs aimed at diabetes prevention, education, and treatment. • In 2024, the US accounted for a larger share of the North America SGLT2 inhibitors market. Pharmaceutical companies in the country invest significantly in research and development (R&D) to enhance the efficacy, safety, and usability of SGLT2 inhibitors. • A few key market players are AstraZeneca; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Eli Lilly and Company; Glenmark Pharmaceuticals Ltd.; Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.); Lexicon Pharmaceuticals, Inc.; Merck & Co., Inc.; Sanofi; and Pfizer Inc.

6. ????? ??: Polaris Market Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Polaris Market Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We at Polaris are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defence, among different ventures present globally. ??????? ????: Polaris Market Research Phone: +1-929-297-9727 Email: sales@polarismarketresearch.com